Arcutis Biotherapeutics, Inc.
General ticker "ARQT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.9B (TTM average)
Arcutis Biotherapeutics, Inc. follows the US Stock Market performance with the rate: 50.0%.
Estimated limits based on current volatility of 2.9%: low 29.15$, high 30.93$
Factors to consider:
- Total employees count: 342 (+15.5%) as of 2024
- Top business risk factors: Limited operating history, Operational and conduct risks, Cybersecurity threats, Regulatory and compliance, Economic downturns and volatility
- Current price 58.6% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [7.16$, 19.65$]
- 2025-12-31 to 2026-12-31 estimated range: [5.73$, 16.20$]
Financial Metrics affecting the ARQT estimates:
- Negative: with PPE of -12.4 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -6.43 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: 41.86 < Shareholder equity ratio, % of 45.16 <= 63.39
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
- Positive: Inventory ratio change, % of -11.17 <= -0.75
- Positive: Investing cash flow per share per price, % of 1.65 > -0.66
- Negative: Industry earnings per price (median), % of -16.34 <= 0
Short-term ARQT quotes
Long-term ARQT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $3.69MM | $59.61MM | $196.54MM |
| Operating Expenses | $305.31MM | $300.71MM | $324.94MM |
| Operating Income | $-301.63MM | $-241.10MM | $-128.40MM |
| Non-Operating Income | $-9.83MM | $-17.93MM | $-10.99MM |
| Interest Expense | $15.65MM | $29.71MM | $27.17MM |
| R&D Expense | $182.44MM | $110.58MM | $76.42MM |
| Income(Loss) | $-311.46MM | $-259.03MM | $-139.39MM |
| Taxes | $0.00MM | $3.11MM | $0.65MM |
| Profit(Loss)* | $-311.46MM | $-262.14MM | $-140.04MM |
| Stockholders Equity | $209.58MM | $88.67MM | $157.54MM |
| Inventory | $7.51MM | $13.13MM | $14.53MM |
| Assets | $449.27MM | $341.37MM | $348.89MM |
| Operating Cash Flow | $-257.71MM | $-247.06MM | $-112.16MM |
| Capital expenditure | $23.28MM | $0.43MM | $0.14MM |
| Investing Cash Flow | $-87.20MM | $180.23MM | $28.82MM |
| Financing Cash Flow | $301.80MM | $101.32MM | $66.20MM |
| Earnings Per Share** | $-5.66 | $-3.78 | $-1.16 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.